Limb ischemia due to spontaneous heparin-induced thrombocytopenia as the primary presentation of acute COVID-19 infection급성 COVID-19 감염의 주요 증상인 자발적 헤파린 유발 혈소판 감소증으로 인한 사지 허혈Case Reports Published on 2022-08-012022-09-12 Journal: Journal of Thrombosis and Thrombolysis [Category] MERS, 진단, [키워드] 2019 coronavirus disease absence activate acute COVID-19 addition administration antibodies characterized complexes COVID-19 develop enzyme-linked immunosorbent had no heparin Hospitalization IgG antibody immunoglobulins, intravenous Infection instances Intravenous immunoglobulin Ischemia less male occur Pain Patient PF4 Platelet platelet activation positive presenting prothrombotic condition reported Serotonin Spontaneous spontaneous heparin-induced thrombocytopenia SRA syndrome thrombocytopenia thrombosis treated Vaccinations [DOI] 10.1007/s11239-022-02676-8 PMC 바로가기 [Article Type] Case Reports
Nonproductive exposure of PBMCs to SARS-CoV-2 induces cell-intrinsic innate immune responsesSARS-CoV-2에 대한 PBMC의 비생산적 노출은 세포 고유의 타고난 면역 반응을 유도합니다Article Published on 2022-08-012022-09-11 Journal: Molecular Systems Biology [Category] SARS, 치료기술, [키워드] absence ACE2 receptor analyzed baseline bystander cell bystander cells Cell COVID-19 Culture Cytokines detectable Ex vivo experiment exposure to expression expression profile expression profiles healthy donor healthy donors human PBMC immune responses in vivo induce infected cell Infection innate immune response Interaction interferon interferon-stimulated gene interferon-stimulated genes interferon-stimulated genes. Invasion ISG ISGs Mild monocyte Monocytes mounted Particle Patient PBMC PBMCs physical proinflammatory cytokines respiratory tract response RT-PCR SARS-CoV SARS-CoV-2 severe COVID-19 Single-cell RNA sequencing STAT stimulate susceptibility triggered virus particle virus particles [DOI] 10.15252/msb.202210961 PMC 바로가기 [Article Type] Article
Antibody Seronegativity in COVID-19 RT-PCR-Positive ChildrenCOVID-19 RT-PCR 양성 아동의 항체 혈청음성도Article Published on 2022-08-012022-09-12 Journal: The Pediatric Infectious Disease Journal [Category] COVID19(2023년), MERS, SARS, 진단, [키워드] absence acute respiratory syndrome Adults antibody coronavirus coronavirus disease COVID-19 Factor household transmission individual individual symptom investigated polymerase chain predict reverse transcription seroconvert [DOI] 10.1097/INF.0000000000003573 PMC 바로가기 [Article Type] Article
Hydroxychloroquine for early treatment of COVID-19: Absence of evidence is different from evidence of absenceCorrespondence Published on 2022-08-012022-10-05 Journal: The Lancet Regional Health - Americas [Category] 치료법, [키워드] absence early treatment Evidence [DOI] 10.1016/j.lana.2022.100314 [Article Type] Correspondence
Out-of-hospital cardiac arrest and in-hospital mortality among COVID-19 patients: A population-based retrospective cohort studyResearch article Published on 2022-08-012022-10-05 Journal: Journal of microbiology, immunology, and infection [Category] 바이오마커, [키워드] 95% confidence interval absence adjusted odds ratio Admission age circulation cohort study Community Comorbidities COVID-19 COVID-19 patient COVID-19 patients death Deceased defined demographics determine discharge disease severity Factor Fever hospital Hypoxemia in-hospital mortality independent predictor Isolation laboratory-confirmed Logistic regression Mortality Occurrence Older age Out-of-hospital cardiac arrest oxygen saturation Patient patients predictor recruited Result retrospective cohort study SARS-CoV-2 symptom onset Taiwan time vital sign were used [DOI] 10.1016/j.jmii.2022.07.009 [Article Type] Research article
Production and characterization of chimeric SARS-CoV-2 antigens based on the capsid protein of cowpea chlorotic mottle virus동백색 반점 바이러스의 캡시드 단백질을 기반으로 하는 키메라 SARS-CoV-2 항원의 생산 및 특성화Article Published on 2022-07-312022-09-11 Journal: International journal of biological macromolecules [Category] COVID19(2023년), SARS, 변종, [키워드] absence Antigen antigens BALB/c mice characterized chimeric Chimeric protein clinical evaluation COVID-19 pandemic Cowpea cultures develop E. coli Efficacy epitope Epitopes expressed expression full-length S protein Humoral response IgG antibody IgG antibody titer immunogenic Inclusion induce interfere mutant offer Pathogens plant plant virus Plant virus. Production Protein purified recognize resulting SARS-CoV-2 SARS-CoV-2 antigen SARS-CoV-2 spike protein spike Spike protein subunit Subunit vaccine subunit vaccines Support the SARS-CoV-2 the vaccine Vaccine vaccine candidate vaccine candidates vaccine platform virus VLP VLPs [DOI] 10.1016/j.ijbiomac.2022.06.021 PMC 바로가기 [Article Type] Article
Coordinated innate and T-cell immune responses in mild COVID-19 patients from household contacts of COVID-19 cases during the first pandemic wave첫 번째 대유행 기간 동안 COVID-19 사례의 가정 접촉에서 경미한 COVID-19 환자의 조정된 타고난 및 T 세포 면역 반응Article Published on 2022-07-272022-09-11 Journal: Frontiers in Immunology [Category] COVID19(2023년), SARS, 치료기술, 치료법, [키워드] absence Alpha anti-N antibodies anti-RBD antibody B-cell cell-mediated response Concordance Contact COVID-19 COVID-19 case COVID-19 cases Cycle threshold value cytokine detectable early immune response early immune responses ELISA enrolled evaluated Factor Follow-up greater high accuracy household household contact household contacts IFN-α IFN-γ IL-1ra IL-1β IL-9 immune responses immunofluorescence Immunopathogenesis indirect immunofluorescence individual innate response interferon interferon-alpha Interferon-alpha (IFN-α) Interferon-gamma Interferon-gamma (IFN-γ) release assay (IGRA) IP-10 MCP-1 membrane mild COVID-19 patient MIP-1β moderate Nasopharyngeal swab Neutralizing antibodies nucleocapsid pandemic peptide peptide pools plasma plasma samples positive positive swab Proteins RANTES RBD reported response returned RT-PCR SARS-CoV-2 SARS-COV-2 infection SARS-CoV-2 swab screened Seroconversion serological serological response significant negative correlation Spike protein stimulated subject Surveillance Swab Swab test swabs T-cell T-cell immune response T-cell Response T-cell specific virus Whole blood [DOI] 10.3389/fimmu.2022.920227 PMC 바로가기 [Article Type] Article
Myocardial Infarction Following COVID-19 Vaccine Administration: Post Hoc, Ergo Propter Hoc?COVID-19 백신 투여 후 심근 경색: 사후, Ergo Propter Hoc?Case Reports Published on 2022-07-272022-09-12 Journal: Viruses [Category] MERS, 진단, [키워드] absence acute cardiovascular events age all subject Analysis antibody cardiac event carrier coronavirus disease COVID-19 COVID-19 vaccination death determinant effective FIVE Genetic testing genotypes heterogenous histopathological information men Mutation Myocardial Myocardial infarction myocarditis pandemic pathophysiological performed Post-mortem Post-vaccine pro-thrombotic reported Research thrombotic Vaccine vaccine administration while yielding [DOI] 10.3390/v14081644 PMC 바로가기 [Article Type] Case Reports
Randomized controlled phase 2 trial of hydroxychloroquine in childhood interstitial lung diseaseClinical Trial Published on 2022-07-232022-10-05 Journal: Orphanet Journal of Rare Diseases [Category] COVID19(2023년), SARS, 임상, [키워드] absence adverse event age all subject approval ARMS calculated Child childhood children Controlled trial double-blind effect size Endpoint evaluated four subject groups HCQ Health Hydroxychloroquine identify Interstitial lung disease Interstitial lung diseases lack lung Lung function multicentre Munich not differ not different offered outcome Oxygenation participated phase 2 trial Placebo placebo-controlled primary endpoint Pulmonary function Quality of life Randomized randomized-controlled trial Registered Registration respiratory rate Respiratory Support secondary study population subject Treatment treatment effects treatment period Trial university were given Withdrawal [DOI] 10.1186/s13023-022-02399-2 PMC 바로가기 [Article Type] Clinical Trial
Favipiravir and/or nitazoxanide: a randomized, double-blind, 2×2 design, placebo-controlled trial of early therapy in COVID-19 in health workers, their household members, and patients treated at IMSS (FANTAZE)Favipiravir 및/또는 nitazoxanide: IMSS(FANTAZE)에서 치료를 받는 의료 종사자, 가족 구성원 및 환자를 대상으로 한 COVID-19 조기 치료에 대한 무작위, 이중 맹검, 2x2 설계, 위약 대조 시험Randomized Controlled Trial Published on 2022-07-222022-09-11 Journal: Trials [Category] COVID19(2023년), SARS, 임상, 치료제, [키워드] 1:1 2×2 design absence Admission antimicrobial Antimicrobials Antiviral effect antiviral therapy Antiviral treatment antivirals appear assigned Asymptomatic blinded to treatment combination therapy Comorbidities Comorbidity Controlled trial COVID-19 COVID-19 disease disease double-blind early disease early phase early treatment example Favipiravir followed by Gender Genetic genetic mutation Health high risk Hospitalization Hypothesis in some include individuals Infection Inflammatory Influenza intensive care investigator investigators later phase morbidity and mortality Mutation mutation rate nitazoxanide obesity older patient outcome pandemic participant patients treated pharmacokinetics phase phase IIa Placebo placebo-controlled placebo-controlled clinical trial placebo-controlled trial positive presence or absence Prevent Primary outcome progression protocol randomised randomised controlled trial Randomized receive replicates SARS-CoV-2 secondary Secondary outcomes security Sepsis severe disease smoking status Social Security Stratification symptomatic symptomatic COVID-19 Symptoms tested the disease therapy those with comorbidity Toxicity treatment allocation Trial upper respiratory tract Viral load virus [DOI] 10.1186/s13063-022-06533-0 PMC 바로가기 [Article Type] Randomized Controlled Trial